Advertisement

Topics

A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g

2010-07-15 17:00:00 | BioPortfolio

Summary

This is a Phase IIb, multicenter, open-label study available to active (Xolair) and control (placebo) subjects who have completed their final visit (or early termination visit, if applicable) for Study Q2788g, who meet the eligibility criteria of this study, and who provide consent to participate in this study.

Study Design

Control: Uncontrolled, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Peanut Hypersensitivity

Intervention

omalizumab

Status

Completed

Source

Genentech

Results (where available)

View Results

Links

Published on BioPortfolio: 2010-07-15T17:00:00-0400

Clinical Trials [243 Associated Clinical Trials listed on BioPortfolio]

A Safety and Efficacy Study of Xolair in Peanut Allergy

This is a 38-week, randomized, double-blind, placebo-controlled, parallel group trial of approximately 150 patients who have a history of immediate hypersensitivity reaction to peanut prot...

Peanut Oral Immunotherapy

This is a study in which increasing amounts of peanut flour are given to the children who are peanut allergic to desensitize them to peanut. The hypothesis is that the peanut allergic pati...

Peanut Sublingual Immunotherapy

The purpose of this study is to evaluate the safety and immune response to daily sublingual (under the tongue) immunotherapy (SLIT) with peanut extract in adults and children with peanut a...

Mucosal Immunotherapy for Peanut Allergy in Young Children

Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit young subjects who have recently been diagnosed wi...

Oral Immunotherapy (OIT) for Peanut Allergy

Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit subjects who have peanut allergy by lowering the r...

PubMed Articles [381 Associated PubMed Articles listed on BioPortfolio]

Long-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial.

Omalizumab has demonstrated therapeutic benefits both in controlled clinical trials and real-life studies. However, research concerning the long-term effects and tolerability of omalizumab is needed. ...

Identification and analysis of peanut-specific T effector and T regulatory cells in children allergic and tolerant to peanut.

Peanut allergy is potentially life-threatening and generally persists lifelong. Recent data suggests the skin may be an important route of initial sensitization to peanut, while early oral exposure to...

Omalizumab Updosing for Better Disease Control in Chronic Spontaneous Urticaria Patients.

The recommended dose of omalizumab for the treatment of chronic spontaneous urticaria (CSU) is 300 mg every 4 weeks, but there is no recommendation for patients who do not benefit from this dose. Our ...

The Effect of Omalizumab on Hematological and Inflammatory Parameters in Patients with Chronic Spontaneous Urticaria.

The mechanism of action of omalizumab in chronic spontaneous urticaria (CSU) is not exactly known. In previous studies, D-dimer which is a fibrin-degradation product and interleukin-31 which has a rol...

Peanut lipids display potential adjuvanticity by triggering a pro-inflammatory response in human keratinocytes.

Currently, the earliest cellular and molecular signals driving allergic sensitization to peanuts are not fully understood, even though peanut allergens have been studied extensively. Meanwhile, lipids...

Medical and Biotech [MESH] Definitions

Allergic reaction to peanuts that is triggered by the immune system.

Allergic reaction to tree nuts and peanuts, including other LEGUMES, that is triggered by the immune system. It includes co-sensitization to other food (e.g., sesame seed).

Allergic reaction to products containing processed natural rubber latex such as rubber gloves, condoms, catheters, dental dams, balloons, and sporting equipment. Both T-cell mediated (HYPERSENSITIVITY, DELAYED) and IgE antibody-mediated (HYPERSENSITIVITY, IMMEDIATE) allergic responses are possible. Delayed hypersensitivity results from exposure to antioxidants present in the rubber; immediate hypersensitivity results from exposure to a latex protein.

Antigen-type substances that produce immediate hypersensitivity (HYPERSENSITIVITY, IMMEDIATE).

Oil derived from PEANUTS.

More From BioPortfolio on "A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial